 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, today announced its development and commercialization partners for South Korea and the Philippines, Telcon RF Pharmaceutical, Inc. Telcon and KPM Tech Co., Ltd. KPM Tech, have received approval from South Koreas MFDS the South Korean equivalent of the U.S. FDA to conduct a Phase 1 clinical study of lenzilumab, which may support potential use in the treatment of hospitalized COVID-19 patients. The study 